MedTrace Logo

Magnesium Supplementation and Blood Pressure Reduction

NCT03688503 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-10-01

No results posted yet for this study

Summary

This double-blind, placebo-controlled randomized clinical trial will test whether a magnesium glycinate supplement (480 mg/day) taken for 12 weeks lowers blood pressure.

Conditions

  • Blood Pressure

Interventions

DIETARY_SUPPLEMENT

magnesium glycinate supplement

magnesium glycinate (480 mg/day)

DIETARY_SUPPLEMENT

placebo

placebo

Sponsors & Collaborators

  • Pure Encapsulations

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2020-01-09
Completion
2025-08-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688503 on ClinicalTrials.gov